Trial
NCT01474434
Efficacy of LCQ908 on Cardiovascular Risk
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Coronary Artery Disease
Intervention
pradigastat (LCQ908)
Why stopped
The study was terminated based on interim analysis. See detailed description.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-14